Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Jones Trading

Jones Trading assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage issued a buy rating and a $45.00 target price on the stock.

PVLA has been the topic of several other reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $39.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Scotiabank initiated coverage on shares of Palvella Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price for the company. TD Cowen assumed coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Cantor Fitzgerald started coverage on Palvella Therapeutics in a report on Wednesday, December 18th. They issued an “overweight” rating on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $43.20.

Palvella Therapeutics Trading Down 2.2 %

Shares of PVLA stock opened at $27.27 on Tuesday. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27. The firm’s fifty day moving average price is $19.36. The firm has a market cap of $306.00 million, a PE ratio of -2.25 and a beta of 0.54.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter worth $8,574,000. BVF Inc. IL acquired a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $8,359,000. Samsara BioCapital LLC purchased a new stake in shares of Palvella Therapeutics in the fourth quarter worth approximately $8,154,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Palvella Therapeutics during the fourth quarter worth approximately $7,847,000. Finally, Adams Street Partners LLC purchased a new position in Palvella Therapeutics during the fourth quarter valued at approximately $4,916,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.